Synovial sarcoma is a type of soft-tissue sarcoma that is primarily found to occur in the arm, leg, or foot, and near joints such as the wrist or ankle. This rare type of cancer is also found in soft tissues in the lung or abdomen. In the U.S., one to two people out of one million people are diagnosed with synovial sarcoma per year. Although the condition can affect individuals of any age, it is more common in teenagers and young adults.
Synovial sarcoma treatment depends on the extent to which the condition has spread in the body. One of the most common forms of treatment is surgery. Synovial can be removed via a procedure called pleurodesis, which involves the removal of a thin film of the substance, along with the affected cells. Another surgical treatment method is called lung transplantation. In this case, excess mesothelioma (cancer of the lung) or peritoneal mesothelioma is removed from the patient's chest or abdomen. Both of these treatments can be used to treat persons who have already been diagnosed with the disease.
A high dose of chemotherapy is generally used in synovial sarcoma treatment. The treatment in focused on reducing the number of remaining microscopic metastases. The outcome of chemotherapy is debatable in the treatment of chemotherapy. However, several studies have demonstrated the efficacy of doxorubicin/ifosfamide treatment in marginally improving the condition of patients.
Cell therapy has demonstrated potential in synovial sarcoma treatment. In November 2020, Adaptimmune Therapeutics plc, a company focused on R&D in cell therapy for the treatment of cancer, presented durability of response data from patients with synovial sarcoma from its Phase 1 ADP-A2M4 trial at the virtual Connective Tissue Oncology Society annual meeting. The company aims to commercialize ADP-A2M4 in the U.S in 2022.
No comments:
Post a Comment